From the official registers: KBO 10 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
JD Pharma is a financial institution. The bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €514,700 and a net result of €48,565. Equity has been growing by about 35% per year since 2018. Its solvency ranks better than 34% of 9,750 sector peers (NACE 64, financial year 2025). The company has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals.
Directors
Directors
1 director
Dieusaert Julie
Current
Mandate history
1 person, 1 in office
- Board
| Name | Functions and periods |
|---|---|
| Dieusaert Julie |
|
The board according to the articles of association
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- Each director alone
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “Natuurlijke personen of rechtspersonen, al dan niet aandeelhouder, één of meer bestuurders”
Articles of association, deed of 06-12-2023
Owners and capital
Capital transactions
Capital over time
- 06-12-2023 Converted to available equity
Other provisions of the articles of association
- Other provisionsThese rules from the articles cover subjects other than the board, the shares, the purpose and the meetings.
- “Bevoegdheden van het bestuursorgaan, meest ruime bevoegdheid voor handelingen nodig of dienstig tot verwezenlijking van het voorwerp tenzij…”“Bestemming van de winst – reserves – interimdividend – tussentijds dividend, verminderd met overgedragen verlies of vermeerderd met…”Liquidation distribution: “Goederen in natura op dezelfde wijze verdeeld, netto actief onder alle aandeelhouders naar verhouding van aantal aandelen”1 more provision in the deed, see the deed of 06-12-2023
Articles of association, deed of 06-12-2023 (in Dutch)